How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,464 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. CAPN3, DCT, MLANA and TYRP1 are overexpressed in skin of vitiligo vulgaris Mexican patients Full Text available with Trip Pro

CAPN3, DCT, MLANA and TYRP1 are overexpressed in skin of vitiligo vulgaris Mexican patients Vitiligo is a disorder causing skin depigmentation, in which several factors have been proposed for its pathogenesis: Environmental, genetic and biological aspects of melanocytes, even those of the surrounding keratinocytes. However, the lack of understanding of the mechanisms has complicated the task of predicting the development and progression. The present study used microarray analysis (...) to characterize the transcriptional profile of skin from Vitiligo Vulgaris (VV) patients and the identified transcripts were validated using targeted high-throughput RNA sequencing in a broader set of patients. For microarrays, mRNA was taken from 20 skin biopsies of 10 patients with VV (pigmented and depigmented skin biopsy of each), and 5 biopsies of healthy subjects matched for age and sex were used as a control. A signature was identified that contains the expression pattern of 722 genes between

2018 Experimental and therapeutic medicine

162. Vitiligo in Children: A Better Understanding of the Disease Full Text available with Trip Pro

Vitiligo in Children: A Better Understanding of the Disease Vitiligo is an important skin disease of childhood. The authors briefly discuss the etiopathobiology, clinics and comorbidities of the disease.

2018 Open access Macedonian journal of medical sciences

163. Unconventional Treatments for Vitiligo: Are They (Un) Satisfactory? Full Text available with Trip Pro

Unconventional Treatments for Vitiligo: Are They (Un) Satisfactory? The authors show a brief overview of the vitiligo's unconventional therapies. A part for well-documented effectiveness of L-phenylalanine, PGE2 and antioxidant agents in the treatment of vitiligo, for the other therapeutical approaches more investigations are needed.

2018 Open access Macedonian journal of medical sciences

164. Herbal Compounds for the Treatment of Vitiligo: A Review Full Text available with Trip Pro

Herbal Compounds for the Treatment of Vitiligo: A Review An overview of unconventional therapies for vitiligo is presented. Some herbal compounds may be considered as valid therapeutic tools for the treatment of vitiligo.

2018 Open access Macedonian journal of medical sciences

165. Vitiligo in Children: A Review of Conventional Treatments Full Text available with Trip Pro

Vitiligo in Children: A Review of Conventional Treatments Vitiligo is an important skin disease of childhood, which may lead to deep psychological trauma, resulting in a poor quality of life and low self-esteem. The Authors discuss a short review of the more conventional therapies available for the treatment of vitiligo in children.

2018 Open access Macedonian journal of medical sciences

166. Vitiligo in Children: What’s New in Treatment? Full Text available with Trip Pro

Vitiligo in Children: What’s New in Treatment? Vitiligo is an acquired chronic hypopigmentary disorder, which usually stars in childhood. The Authors discuss a short review of the more innovative therapies for childhood vitiligo.

2018 Open access Macedonian journal of medical sciences

167. Successful Treatment with UVA 1 Laser of Non - Responder Vitiligo Patients Full Text available with Trip Pro

Successful Treatment with UVA 1 Laser of Non - Responder Vitiligo Patients The Authors discuss their experience in treating non-responder vitiligo patients with a UVA-1 laser. Laser Alba 355® is an innovative device of target UVA - 1 phototherapy. The present report suggests that UVA1 laser could be an applicable therapeutic option in patients with vitiligo, also for the ones who did not respond to the more conventional phototherapies.

2018 Open access Macedonian journal of medical sciences

168. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo Full Text available with Trip Pro

Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo Vitiligo is an acquired pigmentary cutaneous disease, characterised by the progressive loss of melanocytes, resulting in hypopigmented skin areas which progressively become amelanotic. Classically, vitiligo treatments are unsatisfactory and challenging. Despite the continuous introduction of new therapies, phototherapy is still the mainstay for vitiligo (...) (72%) obtained a re-pigmentation rate higher than 75%, with a medium value of 77%. 11 patients (19%) achieved a marked improvement of the clinical findings with a repigmentation rate between 50-75%; 4 patients (8%) showed a moderate response with a lesional repigmentation of 25-50%. Only one patient (1%) had a poor response to the phototherapeutic treatment.Nb - UVB micro-focused phototherapy is one of the most effective therapeutic options for vitiligo treatment. The association of micro-focused

2018 Open access Macedonian journal of medical sciences

169. An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA - 1 Laser Full Text available with Trip Pro

An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA - 1 Laser Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following

2018 Open access Macedonian journal of medical sciences

170. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin Full Text available with Trip Pro

PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin Programmed cell death 1 ligand 1 (PD-L1) is a ligand of programmed cell death 1 (PD-1) that functions as an immune checkpoint by down-regulating immune responses. To determine whether PD-L1 is a therapy target in vitiligo treatment, Pmel-1 vitiligo mice were treated with a PD-L1 fusion protein. Treatment with this fusion protein significantly reversed/suppressed depigmentation development (...) in adult Pmel-1 mice. Mechanistically, enrichment of regulatory T cells (Treg) in the skin was detected after PD-L1 fusion protein treatment in Pmel-1 mice. Furthermore, Tregs abundance was also increased in both the spleen and circulation of Pmel-1 mice treated with PD-L1. These data indicate that PD-L1 protein therapy inhibits the immune response and reverses depigmentation development in Pmel-1 vitiligo mice.

2018 Scientific reports

171. Prostaglandin F2-alpha (PGF2α) in Vitiligo

Prostaglandin F2-alpha (PGF2α) in Vitiligo Prostaglandin F2-alpha (PGF2α) in Vitiligo - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prostaglandin F2-alpha (PGF2α) in Vitiligo The safety and scientific (...) Fathy Elmasry, Cairo University Study Details Study Description Go to Brief Summary: study the cutaneous expression of PGF2α in vitiligo patients and compare it with normal control subjects. Condition or disease Intervention/treatment Phase Vitiligo Other: Skin biopsy Not Applicable Detailed Description: Measurement of tissue levels of PGF2α in vitiligo patients and compare them with healthy controls. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2018 Clinical Trials

172. Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo Full Text available with Trip Pro

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo Vitiligo is a chronic autoimmune disease in which the destruction of melanocytes causes white spots on the affected skin. Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-signal transducer and activator of transcription pathway. The aim of the present study is to explore the possible role of JAK1 in the pathogenesis of vitiligo using (...) immunohistochemical methods.The current study was conducted in a sample of 39 patients who presented with vitiligo and 22 healthy individuals who were age and sex matched as a control group. We used immunohistochemistry to evaluate JAK1 status (intensity and distribution) and assess the percentage of residual melanocytes using human melanoma black 45 (HMB45).Intense and diffuse JAK1 expression was significantly more likely to indicate vitiliginous skin compared to normal skin (p < .001). Strong and diffuse JAK1

2018 Journal of Pathology and Translational Medicine

173. Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer Full Text available with Trip Pro

Vitiligo in a patient undergoing nivolumab treatment for non–small cell lung cancer 30456282 2019 02 26 2352-5126 4 10 2018 Nov JAAD case reports JAAD Case Rep Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer. 1042-1044 10.1016/j.jdcr.2018.08.009 Kosche Cory C Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois. Mohindra Nisha N Department of Internal Medicine, Division of Hematology and Oncology, Northwestern (...) University, Feinberg School of Medicine, Chicago, Illinois. Choi Jennifer N JN Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois. eng Case Reports 2018 11 10 United States JAAD Case Rep 101665210 2352-5126 NSCLC, non–small cell lung cancer PD-1 inhibitor PD-1, programmed cell death protein 1 PD-L1, programmed death ligand 1 adverse event checkpoint inhibitor immunotherapy nivolumab non–small cell lung cancer vitiligo 2018 11 21 6 0 2018 11 21 6 0 2018 11

2018 JAAD Case Reports

174. Malformation de la charnière cervico-occipitale et vitiligo Full Text available with Trip Pro

Malformation de la charnière cervico-occipitale et vitiligo Vitiligo is a relatively common multifactorial polygenetic dermatosis (0.5%-2% of general population) characterized by segmental or nonsegmental cutaneous depigmentation. Chiari malformation is a congenital cervico-occipital junction disease characterized by a migration of a part of the cerebellum through the foramen magnum.The association between these two pathologies is exceptional and poses a cause-effect problem. We here report (...) ). The patient underwent osteo-dural decompression of the posterior fossa with good neurological improvement and repigmentation of patches after 6 months. A few cases have been reported in the literature that show this association. Arguments in favor are: localization of lesions in dermatomes in correspondence with the malformation and regression after surgery. Etiopathogenesis of vitiligo is not clear, then several theories have been proposed to explain its occurrence;autoimmune theory, epidermal adhesion

2018 The Pan African medical journal

175. Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo. (Abstract)

Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo. Narrow-band ultraviolet B (NB-UVB) phototherapy is a mainstay treatment in vitiligo. However, data relative to repigmentation outcome, prognostic factors, and duration of repigmentation are limited.To investigate the quantitative repigmentation outcome of NB-UVB phototherapy in vitiligo, the factors associated with favorable prognosis after NB-UVB, and the duration of repigmentation (...) after NB-UVB discontinuation.Medical records of vitiligo patients who underwent NB-UVB phototherapy at Department of Dermatology, Siriraj Hospital during 2012 to 2016 were retrospectively reviewed. Repigmentation was assessed using Vitiligo Area Scoring Index (VASI) score.Fifty-eight patients were included. All patients received NB-UVB phototherapy twice to three times weekly for a median duration of 12 months. Forty-two patients had non-segmental vitiligo (NSV), and 16 had segmental vitiligo (SV

2018 Journal of Dermatological Treatment

176. Association of human beta-defensin 1 gene polymorphisms with nonsegmental vitiligo. (Abstract)

Association of human beta-defensin 1 gene polymorphisms with nonsegmental vitiligo. Vitiligo is a pigmentation disorder of autoimmune aetiology. Polymorphisms in beta-defensin genes have been linked to a predisposition to some autoimmune disorders.To evaluate the role of polymorphisms in DEFB1, the gene encoding for human beta-defensin (HBD)-1 and its 5' untranslated region in nonsegmental vitiligo.In total, 354 participants [171 patients with non-segmental vitiligo and 183 age and sex-matched (...) healthy controls (HCs)], were genotyped by the PCR-restriction fragment length polymorphism (RFLP) method. For 80 of these individuals (40 patients and -40 HCs) serum HBD-1 was also measured by ELISA.The -44 G allele, CG genotype and GGG haplotype increased the risk for vitiligo (P < 0.02 in all cases), whereas the -20 AA genotype seems to be protective (P = 0.04). Serum HBD-1 levels were lower in patients with vitiligo than in HCs (P < 0.01), as well as in patients with active vitiligo compared

2018 Clinical & Experimental Dermatology

177. Motorized 0.8 mm micro-punch grafting for refractory vitiligo: A retrospective study of 230 cases. (Abstract)

Motorized 0.8 mm micro-punch grafting for refractory vitiligo: A retrospective study of 230 cases. Punch grafting for vitiligo is time-consuming and can result in cobblestone-like appearances. We devised a motorized 0.8-mm micropunch grafting procedure to overcome these limitations.To assess the therapeutic effectiveness and adverse events associated with micropunch grafting in refractory vitiligo.We retrospectively reviewed 230 cases in 208 patients with stable vitiligo who underwent motorized (...) %). Overall, the treatment was tolerable.This was a retrospective study.Micropunch grafting using a motorized 0.8-mm punch can successfully treat refractory vitiligo with short procedure times and excellent outcomes. This technique could be a rapid and convenient surgical option with acceptable adverse events and is promising for treating refractory vitiligo on an outpatient basis, particularly in patients who are unlikely to tolerate prolonged surgery.Copyright © 2018 American Academy of Dermatology, Inc

2018 Journal of American Academy of Dermatology

178. Vitiligo remitting with tocilizumab. Full Text available with Trip Pro

Vitiligo remitting with tocilizumab. 29888453 2019 01 18 1468-3083 33 1 2019 Jan Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Vitiligo remitting with tocilizumab. e20 10.1111/jdv.15117 Bunker C B CB University College London Hospitals, 250 Euston Road, London, NW1 2AF, UK. Manson J J University College London Hospitals, 250 Euston Road, London, NW1 2AF, UK. eng Letter 2018 06 28 England J Eur Acad Dermatol Venereol 9216037 0926-9959 2018 6

2018 Journal of the European Academy of Dermatology and Venereology

179. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. (Abstract)

Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 28300320 2018 08 20 2018 08 20 1365-2230 42 3 2017 Apr Clinical and experimental dermatology Clin. Exp. Dermatol. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 363-366 10.1111/ced.13056 BinSheikhan S S Department of Dermatology, Zayed Military Hospital, Abu Dhabi, United Arab Emirates (...) . Al Abadie M M http://orcid.org/0000-0002-0727-4632 Department of Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, and Medical School, Birmingham, West Midlands, UK. eng Journal Article Randomized Controlled Trial England Clin Exp Dermatol 7606847 0307-6938 IM Adolescent Adult Aged Combined Modality Therapy Female Humans Lasers, Excimer therapeutic use Low-Level Light Therapy adverse effects instrumentation Male Middle Aged Needles Vitiligo radiotherapy surgery Young Adult 2016 04 06

2018 Clinical and experimental dermatology Controlled trial quality: uncertain

180. "Vitiligo and major depressive disorder: a bidirectional population-based cohort study". (Abstract)

"Vitiligo and major depressive disorder: a bidirectional population-based cohort study". Vitiligo patients often report their mental health has an impact on their skin. However, it is unknown as to whether a common mental disorder such as major depressive disorder (MDD) can also precipitate the onset of vitiligo.Evaluate a bidirectional relationship between MDD and vitiligo using The Health Improvement Network (THIN) database.Incident MDD and referent cohorts were followed until the development (...) of vitiligo. Additionally, incident vitiligo and referent cohorts were followed until the development of MDD. Cox proportional-hazards models were used, adjusting for numerous covariates.In adjusted models, MDD patients (n=405,397) were at a 64% increased risk of vitiligo (HR=1.64, 95%CI: 1.43-1.87, p<0.0001) compared to the referent cohort (n=5,739,048). This risk was decreased in patients using antidepressants. Compared to the referent cohort (n=6,137,696), patients with vitiligo (n= 7,104) that were

2018 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>